Patient
SITE013-0183
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE013 (USA) (Dr. Clarke)
consented 2026-04-13
Adverse events
7
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 7
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 72); relationship: NOT RELATED
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-23 (study day 68); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 62); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 54); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-16 (study day 31); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 23); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-25 (study day 9); relationship: NOT RELATED; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.